Results 71 to 80 of about 15,200 (191)

Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma [PDF]

, 2017
Immunoglobulin G (IgG) metabolism has received much attention in the literature for two reasons: (i) IgG homeostasis is regulated by the neonatal Fc receptor (FcRn), by a pH-dependent and saturable recycling process, which presents an interesting ...
Arnulf, Bertrand, Avet-Loiseau, Hervé, Chappell, Michael J., Decaux, Olivier, Dejoie, Thomas, Evans, Neil D., Fouquet, Guillemette, Guidez, Stéphanie, Harding, Stephen, Harel, Stéphanie, Hebraud, Benjamin, Javaugue, Vincent, Kendrick, Felicity, Leleu, Xavier, Moreau, Philippe, Richez, Valentine, Schraen, Susanna, Touzeau, Cyrille   +17 more
core   +2 more sources

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, EarlyView.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

Brain, Behavior, & Immunity - Health
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain, Annabelle Emery, Frankie F. Brown, Adam J. Causer, Rebecca Oliver, Rachel Eddy, Shoji Leach, John Graby, Daniel Augustine, Sally Moore, Josephine Crowe, James Murray, James E. Turner, John P. Campbell   +13 more
doaj   +1 more source

Nuevos usos de la talidomida: Del desastre a la esperanza [PDF]

, 2017
Trabajo fin de grado en EnfermeríaLa talidomida se mantiene como uno de los medicamentos más controvertidos históricamente debido a que provocó a nivel mundial numerosos casos de embriopatías en los niños durante la década de los 60.
Williams Aguirre, Ana
core  

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine

International Journal of Infectious Diseases
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment.
Simon B. Gressens, Vincent Enouf, Antoine Créon, Giovanna Melica, Francois Lemonnier, Jehan Dupuis, Taoufik El Gnaoui, Mohammad Hammoud, Karim Belhadj, Corinne Haioun, Anne Le Bouter, Sebastien Gallien, Fabien Le Bras, Slim Fourati   +13 more
doaj   +1 more source

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Asian Journal of Transfusion Science, 2017
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 ...
Mei-Hwa Lin, Fei-Yun Liu, Hsiu-Mien Wang, Hsin-Ching Cho, Shyh-Chyi Lo   +4 more
doaj   +1 more source

Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients (n = 6555), both adults and children, over a 30‐year period in Finland.
Terhi K. Friman, Birgitta Salmela, Ilkka Helanterä, Fredrik Åberg, Timo Jahnukainen, Maija Halme, Samuli Vaittinen, Jyri Lommi, Markku O. Pentikäinen, Panu E. Kovanen, Sirpa Leppä, Riikka Räty   +11 more
wiley   +1 more source

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

OncoImmunology, 2019
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells.
Maria C. Ochoa, Elisabeth Perez-Ruiz, Luna Minute, Carmen Oñate, Guiomar Perez, Inmaculada Rodriguez, Aintzane Zabaleta, Diego Alignani, Myriam Fernandez-Sendin, Ascension Lopez, Aura Muntasell, Miguel F. Sanmamed, Bruno Paiva, Miguel Lopez-Botet, Pedro Berraondo, Ignacio Melero   +15 more
doaj   +1 more source

The non-coding RNA landscape of plasma cell dyscrasias [PDF]

, 2020
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A, et al,, Morelli, Eugenio, Rocca, Roberta   +3 more
core   +1 more source